Research To Practice | Oncology Videos
Featuring perspectives from Dr Ana C Garrido-Castro and Prof Peter Schmid, including the following topics: Introduction: Legendary Figures in Breast Cancer Research (0:00) Case: A woman in her early 80s, a current smoker with a history of myocardial infarction and stroke, who develops recurrent triple-negative breast cancer (TNBC) — Justin Favaro, MD, PhD (6:44) Case: A woman in her late 60s with metastatic TNBC and a PD-L1 level of 20% who receives chemotherapy/pembrolizumab followed by sacituzumab govitecan — Priya Rudolph, MD, PhD (25:08) Case: A woman in her late 60s with...
info_outlineResearch To Practice | Oncology Videos
Featuring an interview with Dr Neel Pasricha, including the following topics: Anatomy and physiology of the cornea; intersection of ophthalmology and oncology for patients receiving antibody-drug conjugates (ADCs) (0:00) Association of corneal toxicities with ADCs (4:56) Dose and schedule modifications to mitigate ocular toxicities associated with belantamab mafodotin and other ADCs (9:02) Spectrum and severity of corneal toxicities associated with datopotamab deruxtecan (14:44) Role of optometrists and ophthalmologists in screening for and management of ocular toxicities (17:55) Other ocular...
info_outlineResearch To Practice | Oncology Videos
Featuring perspectives from Prof Rebecca A Dent, Dr Hans Lee, Dr Neel Pasricha and Dr Tiffany A Richards, including the following topics: Introduction: The Patient Experience (0:00) Managing Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies — Dr Pasricha (10:28) Ocular Toxicities in Multiple Myeloma (45:33) Ocular Toxicities in Breast Cancer (50:34)
info_outlineResearch To Practice | Oncology Videos
Featuring an interview with Dr Jacob Sands, including the following topics: Management of Adverse Events of Special Interest Associated with Datopotamab Deruxtecan (Dato-DXd) (0:00) Heist RS et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. Sands J et al. Analysis of drug-related interstitial lung disease (ILD) in patients (pts) treated with datopotamab deruxtecan (Dato-DXd). ASCO 2024;. Intracranial Efficacy of Dato-DXd for Previously...
info_outlineResearch To Practice | Oncology Videos
Featuring perspectives from Dr Komal Jhaveri and Dr Virginia Kaklamani, including the following topics: Introduction: ER-Positive Metastatic Breast Cancer — Bringing Research Data into Practice (0:00) Key Issues from the General Medical Oncologists (GMO) Survey (3:43) Faculty Cases and GMO Questions (44:43)
info_outlineResearch To Practice | Oncology Videos
Featuring an interview with Ms Charise Gleason, including the following topics: Progress and change in the management of multiple myeloma (MM) (0:00) Patient- and disease-specific factors guiding therapeutic decision-making for newly diagnosed MM (5:11) Role of anti-CD38 antibodies in the management of MM (12:14) Emerging treatment options for smoldering myeloma (23:08) Optimizing long-term outcomes for patients with MM (25:38) Tailoring therapy for older adults and patients with preexisting comorbidities (29:59) Case: A woman in her early 80s with newly diagnosed transplant-ineligible MM who...
info_outlineResearch To Practice | Oncology Videos
Featuring an interview with Prof Xavier Leleu including the following topics: Introduction: Historical treatment advances in multiple myeloma (MM) (0:00) Contemporary treatment for patients with newly diagnosed MM who are eligible for transplant (13:18) Prognosis and life expectancy for patients with MM (19:39) Mechanistic differences among anti-CD38 monoclonal antibodies (27:05) Routes of administration of anti-CD38 monoclonal antibodies (30:21) Background and treatment of smoldering myeloma (41:05) Treatment for older patients with newly diagnosed MM who are not eligible for transplant...
info_outlineResearch To Practice | Oncology Videos
Featuring an interview with Dr Erika Hamilton, including the following topics: Monitoring, mitigating and managing adverse events with antibody-drug conjugates (ADCs) for breast cancer (0:00) Heist RS et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. Management protocols for adverse events associated with sacituzumab govitecan (7:49) García JMP et al. Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients with...
info_outlineResearch To Practice | Oncology Videos
Featuring perspectives from Dr Natalie S Callander and Dr Sagar Lonial, including the following topics: Introduction (0:00) A Farmer with Myeloma; Is Myeloma the New Chronic Myeloid Leukemia? (2:06) Clinical Trials (12:34) Chimeric Antigen Receptor Therapy (16:11) Bispecific Antibodies (21:38) Antibody-Drug Conjugates; a Patient on Belantamab Mafodotin for 3 Years (30:45) Treatment Options for Relapsed Disease (40:46) Neuropathy (44:43) Alternative Therapies (48:36) 164 Questions (53:20)
info_outlineResearch To Practice | Oncology Videos
Featuring perspectives from Dr Haley Ellis and Dr James J Harding, including the following topics: Introduction: Is Biliary Tract Cancer (BTC) the New Non-Small Cell Lung Cancer? … Why? (0:00) Case: A woman in her mid 70s with metastatic cholangiocarcinoma receives first-line gemcitabine/cisplatin with durvalumab — Warren S Brenner, MD (8:42) Case: A man in his late 70s with metastatic biliary cancer (HER2 IHC 2+) discontinues first-line chemotherapy/immunotherapy because of exacerbation of Crohn’s disease — Neil Morganstein, MD (17:48) Case: A man in his early 70s with...
info_outlineFeaturing perspectives from Dr Benjamin Levy, including the following topics:
- Introduction: The Boards (0:00)
- Immune Checkpoint Inhibition for Localized Non-Small Cell Lung Cancer (NSCLC) (11:43)
- Immunotherapy for Metastatic NSCLC (24:41)
- Antibody-Drug Conjugates (33:46)
- Novel Bispecific Antibodies (42:08)
- Journal Club with Dr Levy (51:28)